Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer

NEXT STORY
People with disabilities support the USNS Comfort mission to aid New York City
PREV STORY
Biosimilars Market by Product, Manufacturing & Indication and Region – Global Forecast to 2025
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors

author_avatar
NASDAQ Market News

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018

Reports Net Revenues of $58.4 Million for the Three Months Ended March 31, 2018 ...

author_avatar
NASDAQ Market News

Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings

Study results to be presented at NASPGHAN demonstrate reductions in bile acids and bilirubin are ...

author_avatar
NASDAQ Market News